These sources of variability complicate reproducible translation: an intervention that raises colonic butyrate and sensitizes tumor cells to ferroptosis in one patient may have muted or even opposite effects in another whose microbiome metabolizes substrates differently or whose tumor exhibits alternative antioxidant compensation (e.g., NRF2 activation or FSP1 upregulation). Here, AIFM2 is linked to neoplasm.